ArticleCancer immunology, immunotherapy : CII2025

Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in patients with resectable stage III NSCLC? A two-center real-world study.

Song Guan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.